Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou, Zubing Mei. Endocr Connect 2019
Times Cited: 7
Times Cited: 7
Times Cited
Times Co-cited
Similarity
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
57
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
57
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
57
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N Engl J Med 1993
57
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
42
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
42
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
42
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
42
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
42
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
42
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
28
Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab Res Rev 2019
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab Res Rev 2019
28
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
28
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol Ther 2018
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol Ther 2018
28
Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.
David M Nathan, Paula McGee, Michael W Steffes, John M Lachin. Diabetes 2014
David M Nathan, Paula McGee, Michael W Steffes, John M Lachin. Diabetes 2014
28
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Kurt J Griffin, Paul A Thompson, Michael Gottschalk, Jennifer H Kyllo, Alex Rabinovitch. Lancet Diabetes Endocrinol 2014
Kurt J Griffin, Paul A Thompson, Michael Gottschalk, Jennifer H Kyllo, Alex Rabinovitch. Lancet Diabetes Endocrinol 2014
28
The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
28
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
28
Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
Neha S Patel, Michelle A Van Name, Eda Cengiz, Lori R Carria, Stuart A Weinzimer, William V Tamborlane, Jennifer L Sherr. Diabetes Technol Ther 2017
Neha S Patel, Michelle A Van Name, Eda Cengiz, Lori R Carria, Stuart A Weinzimer, William V Tamborlane, Jennifer L Sherr. Diabetes Technol Ther 2017
28
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
John M Lachin, Saul Genuth, Patricia Cleary, Matthew D Davis, David M Nathan. N Engl J Med 2000
John M Lachin, Saul Genuth, Patricia Cleary, Matthew D Davis, David M Nathan. N Engl J Med 2000
28
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
28
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
28
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
28
Renal effects of glucagon-like peptide in rats.
Carol Moreno, Mahesh Mistry, Richard J Roman. Eur J Pharmacol 2002
Carol Moreno, Mahesh Mistry, Richard J Roman. Eur J Pharmacol 2002
14
Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.
Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, Nancy Amaral Rebouças. Am J Physiol Renal Physiol 2008
Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, Nancy Amaral Rebouças. Am J Physiol Renal Physiol 2008
14
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
K Aaboe, F K Knop, T Vilsbøll, C F Deacon, J J Holst, S Madsbad, T Krarup. Diabetes Obes Metab 2010
K Aaboe, F K Knop, T Vilsbøll, C F Deacon, J J Holst, S Madsbad, T Krarup. Diabetes Obes Metab 2010
14
The physiological role of glucagon-like peptide-1 in the regulation of renal function.
Lívia X S Farah, Vanessa Valentini, Thaissa D Pessoa, Gerhard Malnic, Alicia A McDonough, Adriana C C Girardi. Am J Physiol Renal Physiol 2016
Lívia X S Farah, Vanessa Valentini, Thaissa D Pessoa, Gerhard Malnic, Alicia A McDonough, Adriana C C Girardi. Am J Physiol Renal Physiol 2016
14
Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.
W Todd Cade. Phys Ther 2008
W Todd Cade. Phys Ther 2008
14
PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
14
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Marcel H A Muskiet, Mark M Smits, Linde M Morsink, Michaela Diamant. Nat Rev Nephrol 2014
Marcel H A Muskiet, Mark M Smits, Linde M Morsink, Michaela Diamant. Nat Rev Nephrol 2014
14
Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.
Holger Fuchs, Rudolf Binder, Andreas Greischel. Biopharm Drug Dispos 2009
Holger Fuchs, Rudolf Binder, Andreas Greischel. Biopharm Drug Dispos 2009
14
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka,[...]. Clin Pharmacol Ther 2005
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka,[...]. Clin Pharmacol Ther 2005
14
Angiotensin II stimulates trafficking of NHE3, NaPi2, and associated proteins into the proximal tubule microvilli.
Anne D M Riquier-Brison, Patrick K K Leong, Kaarina Pihakaski-Maunsbach, Alicia A McDonough. Am J Physiol Renal Physiol 2010
Anne D M Riquier-Brison, Patrick K K Leong, Kaarina Pihakaski-Maunsbach, Alicia A McDonough. Am J Physiol Renal Physiol 2010
14
DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
14
DPP4 inhibitors: a new approach in diabetes treatment.
John Doupis, Aristidis Veves. Adv Ther 2008
John Doupis, Aristidis Veves. Adv Ther 2008
14
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2011
Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2011
14
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
14
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
14
Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
Xiaodan Zhang, Qingyu Zhao. J Hypertens 2016
Xiaodan Zhang, Qingyu Zhao. J Hypertens 2016
14
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
14
Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.
Akira Mima, Junko Hiraoka-Yamomoto, Qian Li, Munehiro Kitada, Chenzhong Li, Pedro Geraldes, Motonobu Matsumoto, Koji Mizutani, Kyoungmin Park, Christopher Cahill,[...]. Diabetes 2012
Akira Mima, Junko Hiraoka-Yamomoto, Qian Li, Munehiro Kitada, Chenzhong Li, Pedro Geraldes, Motonobu Matsumoto, Koji Mizutani, Kyoungmin Park, Christopher Cahill,[...]. Diabetes 2012
14
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Keizo Kanasaki. Clin Sci (Lond) 2018
Keizo Kanasaki. Clin Sci (Lond) 2018
14
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.
Rolee Pathak, Mary Barna Bridgeman. P T 2010
Rolee Pathak, Mary Barna Bridgeman. P T 2010
14
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Arthur J Bergman, Josee Cote, Bingming Yi, Thomas Marbury, Suzanne K Swan, William Smith, Keith Gottesdiener, John Wagner, Gary A Herman. Diabetes Care 2007
Arthur J Bergman, Josee Cote, Bingming Yi, Thomas Marbury, Suzanne K Swan, William Smith, Keith Gottesdiener, John Wagner, Gary A Herman. Diabetes Care 2007
14
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Anthony H Barnett. Adv Ther 2011
Anthony H Barnett. Adv Ther 2011
14
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
Eleonora Russo, Giuseppe Penno, Stefano Del Prato. Diabetes Metab Syndr Obes 2013
Eleonora Russo, Giuseppe Penno, Stefano Del Prato. Diabetes Metab Syndr Obes 2013
14
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
14
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Erin E Mulvihill, Daniel J Drucker. Endocr Rev 2014
Erin E Mulvihill, Daniel J Drucker. Endocr Rev 2014
14
Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
Aastha Chawla, Rajeev Chawla, Shalini Jaggi. Indian J Endocrinol Metab 2016
Aastha Chawla, Rajeev Chawla, Shalini Jaggi. Indian J Endocrinol Metab 2016
14
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.